Track market-moving stories before they get noisy

- Foreign ownership rises to 51% based on strong overseas performance and enhanced shareholder returns

- CEO Bang Kyung-man and senior management actively communicate with global investors through Overseas Non-Deal Roadshows (NDRs)

, /PRNewswire/ -- KT&G (KRX: 033780) announced on the 10th that BlackRock Fund Advisors, the world's largest asset manager, has acquired a 6.15% stake in the company for investment purposes.

According to the DART system, BlackRock Fund Advisors disclosed that it held a 5.01% stake in KT&G at the end of January. Subsequently, the company acquired an additional 467,350 shares over the following four months. Accordingly, BlackRock Fund Advisors' stakeholding ratio increased by 1.14 percentage points to 6.15%.

Previously on June 9th, Capital Research and Management Company, one of the largest U.S. asset managers, disclosed that it had increased its stake in KT&G to 7.21%. As global asset managers continue to expand their holdings in KT&G, the company's foreign ownership ratio has reached 51.24% as of the 10th.

The increase in ownership by foreign investors is attributed to KT&G's strong overseas performance and enhanced shareholder returns. In addition, CEO Bang Kyung-man and senior management have continuously conducted Overseas Non-Deal Roadshows (NDRs) and actively communicated with the capital market, which has received positive evaluations from global investors.

On one hand, KT&G saw good results in Q1, with a revenue of KRW 1.7036 trillion and operating profit of KRW 364.5 billion on a consolidated basis, a 14.3% and 27.6% YoY growth respectively, observing structural growth.

Furthermore, KT&G plans to announce a new shareholder return policy in H2 focusing on dividend reinforcement. Supported by strong earnings momentum from the global cigarette business, the company continues to receive favorable evaluations from both domestic and international capital markets.

A KT&G spokesperson stated that "the increase in ownership by global asset managers serves as a testament to the capital market's confidence in the company's mid- to long-term vision and future growth potential. In the future, the company will continue to enhance corporate value through structural profit growth in its core businesses, including the global cigarette business, and industry-leading shareholder returns."

SOURCE KT&G Corporation

Also from this source

Other large asset managers made similarly eye-popping requests.

“The massive size of the SpaceX IPO alone, under normal circumstances, would justify careful SEC review and attention to investor needs. But these are not normal circumstances: a number of additional factors exacerbate concerns and require action by the SEC to meet its investor protection and market integrity mandates by delaying the IPO.

Shareholders asked to redeem more than last quarter though withdrawals will be capped at 5% again

NEW YORK--(BUSINESS WIRE)--BlackRock has one of the most comprehensive investment platforms in the industry, providing investors with choice to meet their individual needs. Investors continue to turn to BlackRock to unlock the full potential of their portfolios, as evidenced by nearly $2 trillion of net inflows in the past five years globally.1 As we evolve our global investment platform, we also continually assess how our funds are meeting investors' investment objectives and the needs of our.

watch now

Americans have spent nearly $450 extra per household on rising energy costs during the Iran war, according to an analysis shared exclusively with CNBC's Steve Liesman.

The average household has shelled out $447.19 for additional fuel-related expenses since the conflict began on Feb. 28, data from Moody's Analytics found. That's cumulatively cost American consumers nearly $60 billion as gas prices and airline fares have surged.

Moody's data puts a dollar amount on a portion of the economic pain Americans are feeling as the war reaches its three-month mark. Higher energy costs can force consumers to raid their savings and lean more on debt to cover expenses.

"Unless the war ends soon, financially pressed consumers will have no option but to turn more cautious in their spending, threatening the already soft economy," said Mark Zandi, Moody's chief economist.

If prices stay at current levels, the average household could take a hit of almost $2,000 at the one-year mark of the war, Zandi said.

Roughly half of the increased energy spending so far comes from higher gasoline prices. The average unleaded gallon in the U.S. cost about $4.39 on Friday, up more than 47% since the start of March, according to AAA.

Pricier diesel, which is used in vehicles like delivery trucks and boats, has resulted in more than $20 billion in additional expenses for consumers. The price of diesel has similarly jumped roughly 47% since the beginning of March to around $5.52 a gallon, per AAA.

Consumers have given up nearly $10 billion as a result of rising costs for jet fuel. Airline fares climbed more than 20% in April compared with 12 months ago, federal government inflation data shows.

That nearly $450 impact more than erased the boost of $384 per household from bigger tax returns this year under President Donald Trump's "big, beautiful bill," according to Moody's. Most of the benefits from larger tax cuts have already been exhausted, Zandi said.

Goldman Sachs said it expects higher energy prices to "erode" consumers' spending power through the rest of 2026. It should specifically hamper lower-income households that spend a larger percentage of budgets on food and energy, the bank said.

Costco saw "record-breaking" gas volumes at the end of its fiscal quarter as drivers sought out its lower-priced fuel, the wholesaler said Thursday. McDonald's CEO Chris Kempczinski warned this month that consumer spending — specifically among lower-income cohorts — "may be getting a little bit worse" as energy prices pinch pocketbooks.

Turning to savings, debtConsumer spending rose 0.5% from March to April, according to government figures released Thursday. But other data points show that isn't necessarily coming from discretionary funds.

Income growth came in flat for April, missing the consensus forecast among economists for a 0.4% increase.

The personal savings rate fell to 2.6% in April, one of the lowest readings since the global financial crisis. It's far off highs above 31% seen in 2020, signaling that consumers have continued to spend through pandemic stimulus and rainy-day stashes amid inflationary pressures.

American credit card debt came in at $1.25 trillion in the first quarter, up close to 6% from a year ago, the New York Federal Reserve said this month. That's near the all-time record set at the end of 2025.

"Consumers are increasingly facing an income squeeze, which is forcing them to use savings, credit and wealth to sustain their spending patterns," said Gregory Daco, chief economist at EY-Parthenon. "What we're seeing is, essentially, the use of savings to offset weak income growth."

— CNBC's Steve Liesman and Betsy Spring contributed to this report.

Key Takeaways MCD posted 3.8% global comparable sales growth and gained share across nearly all top markets.MCD expanded U.S. value offerings with sub-$3 items and a $4 Breakfast Meal Deal.MCD reported share gains in the U.K., Germany and Australia through localized value programs. McDonald’s Corporation (MCD - Free Report) appears to be strengthening its position in the fast-food value battle as consumers remain cautious about spending. During its first-quarter 2026 earnings call, management emphasized that value has become the foundation of the company’s growth strategy, helping it to attract customers despite ongoing economic uncertainty.

The company delivered solid first-quarter results, with global comparable sales rising 3.8% and market share gains across nearly all of its top markets. Management credited this performance to a combination of affordable menu offerings, effective marketing campaigns and targeted menu innovation. McDonald’s leadership reiterated that it does not intend to lose its competitive edge on affordability.

In the United States, McDonald’s expanded its value platform by introducing an everyday menu featuring items priced below $3 and a $4 Breakfast Meal Deal. These additions complement existing meal bundles and are designed to appeal to budget-conscious consumers. The company noted that earlier value initiatives successfully improved perceptions of affordability while helping regain traffic from lower-income customers who had reduced spending amid inflationary pressures.

McDonald’s value-focused approach is not limited to the U.S. International markets such as the United Kingdom, Germany and Australia also reported strong performance, supported by affordable meal bundles and localized value programs. These markets delivered share gains even as quick-service restaurant traffic weakened in many regions.

While management acknowledged that rising fuel costs and economic uncertainty continue to pressure lower-income consumers, McDonald’s believes its combination of value, marketing and menu innovation positions it well to outperform competitors. The company’s ability to gain market share in a challenging environment suggests that its value strategy is resonating. For now, McDonald’s appears to be winning the value wars by giving customers affordable options without sacrificing brand relevance or growth momentum.

How Rivals Are Responding to the Value-Focused ConsumerMcDonald’s is not the only restaurant chain competing for budget-conscious customers. Two major rivals, Restaurant Brands International's (QSR - Free Report) Burger King and Wendy’s Company (WEN - Free Report) , have also intensified their value offerings as consumers become more selective with discretionary spending.

Burger King has leaned heavily on limited-time value meals and digital promotions to drive traffic. The chain has paired affordability initiatives with menu upgrades and restaurant remodels to improve customer perception. While these efforts have supported traffic trends, McDonald’s broader scale and more established value platform give it a competitive advantage in reaching a wider customer base.

Meanwhile, Wendy’s has focused on its value menu and app-based discounts to attract cost-conscious diners. The company continues to promote low-priced meal bundles while balancing profitability through premium menu innovation. However, Wendy’s smaller international footprint limits its ability to replicate value-driven success across multiple markets.

Compared with both competitors, McDonald’s benefits from a globally coordinated strategy that combines affordable pricing, strong marketing campaigns and menu innovation. This integrated approach has helped the company gain market share in several key regions, positioning it favorably in the ongoing battle for value-seeking consumers.

MCD’s Price Performance, Valuation & EstimatesMcDonald’s shares have declined 10.7% in the past year, underperforming the Zacks Retail - Restaurants industry, the broader Retail and Wholesale sector and the S&P 500 index.

MCD 1-Year Price Performance
Image Source: Zacks Investment Research

In terms of its forward 12-month price-to-earnings ratio, MCD is trading at 20.8, down from the industry’s 22.43.

MCD P/E (F12M)
Image Source: Zacks Investment Research

MCD’s earnings estimates for 2026 and 2027 have trended downward in the past 30 days. The revised estimates for 2026 and 2027 imply year-over-year growth of 6% and 9.2%, respectively.

Image Source: Zacks Investment Research

MCD currently carries a Zacks Rank #4 (Sell).

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

McDonald’s is set to announce a new corporate strategy at a worldwide gathering for franchisees and suppliers in Las Vegas, the company said in a statement on Monday.

The strategy, which the burger giant is calling “McDonald’s>NEXT,” focuses on increasing automation, raising standards for hospitality, leaning on social media for marketing, and making its sandwiches and fries taste better.

McDonald’s, the world’s largest fast food chain by sales, said details, including financial figures would be released at an investor event in September.

The strategy, which the burger giant is calling “McDonald’s>NEXT,” focuses on increasing automation, raising standards for hospitality, leaning on social media for marketing, and making its sandwiches and fries taste better. AP “While perceptions of our value have rebounded in most markets, it’s a reminder that we need to earn, and re-earn, each and every visit,” said CEO Chris Kempczinski in a company-wide memo. Chris Kempczinski/Instagram The broad strategy’s announcement comes as McDonald’s tries to hold on to lower-income consumers who have cut back on restaurant visits after years of higher prices. The company has leaned on value meals, loyalty program offers and limited-time menu items to drive traffic.

The share of US customers who said the chain offers good value fell from 55% to roughly 40% between 2020 and 2024, and has largely stayed there since, according to surveys from UBS Evidence Labs shared with Reuters last month.

“While perceptions of our value have rebounded in most markets, it’s a reminder that we need to earn, and re-earn, each and every visit,” said CEO Chris Kempczinski in a company-wide memo shared with Reuters.

With the new strategy, the company aims to make its restaurants “easier to run and more enjoyable to visit,” McDonald’s chief restaurant experience executive Jill McDonald said in a statement.

McDonald’s previous corporate strategy, announced in 2020, was called “Accelerating the Arches” and focused in part on digital sales and increased marketing.

Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases Travere Therapeutics, Inc., (Nasdaq: TVTX) today announced that it has entered into an exclusive licensing and collaboration agreement with Everest Medicines for the development and commercialization of civorebrutinib (also known as EVER001), a potential best-in-class oral, covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor in all markets outside China and certain countries in East and Southeast Asia.

“Civorebrutinib represents a strategic and complementary addition to our rare kidney disease portfolio, with the potential to become a best-in-class therapy across multiple immune-mediated rare kidney diseases,” said Eric Dube, Ph.D., president and chief executive officer of Travere Therapeutics. “Patients living with rare kidney diseases still face significant unmet need, and we believe the progress made to date in IgAN and FSGS is only the beginning of what is possible for these communities. Travere has helped to deliver important firsts in these diseases, and we believe our expertise, infrastructure and deep commitment to the rare kidney community position us well to continue advancing innovation for patients. With proof-of-concept data in primary membranous nephropathy, a differentiated profile as an oral, reversible BTK inhibitor, and expected broad mechanistic applicability across diseases such as immune-mediated FSGS, minimal change disease and beyond, we believe civorebrutinib has the potential to meaningfully advance the treatment paradigm for rare kidney disease patients.”

“This collaboration with Travere brings together deep expertise in kidney disease development and commercialization and we look forward to advancing civorebrutinib in primary membranous nephropathy, immune-mediated FSGS, and minimal change disease, delivering transformative therapies for patients with serious kidney diseases worldwide,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “As a differentiated, potential best-in-class therapy, civorebrutinib has demonstrated encouraging efficacy in primary membranous nephropathy. With its highly selective and reversible covalent mechanism of action, it is well positioned to advance in development across multiple immune-mediated kidney indications. Everest remains committed to our dual-engine strategy of business development partnerships and in-house R&D. This collaboration will accelerate the global development and potential commercialization of civorebrutinib, expanding its clinical and future commercial value in autoimmune kidney diseases and the ability to deliver more innovative treatment options to patients.”

Civorebrutinib is an investigational oral, covalent reversible BTK inhibitor designed to provide differentiated efficacy, safety and convenience for patients with rare, immune-mediated kidney diseases, including primary membranous nephropathy (PMN), with planned evaluation in focal segmental glomerulosclerosis (FSGS), minimal change disease (MCD) and potentially additional indications. BTK is a key mediator of B-cell receptor signaling and plays an important role in B-cell activation, maturation, proliferation, and differentiation into antibody-producing cells.

In immune-mediated kidney diseases, B-cell activation and autoantibody production are believed to contribute directly to kidney injury. Civorebrutinib has demonstrated proof of concept in a Phase 1/2 clinical trial of patients with PMN. The previously reported Phase 1/2 data demonstrated rapid and sustained reductions in anti-PLA2R autoantibodies and proteinuria, with high rates of immunologic and clinical remission and stable kidney function through 52 weeks of follow-up. Civorebrutinib has been generally well tolerated throughout the development program to date.

As innovation in rare kidney diseases continues to accelerate, patients still face significant unmet need and limited treatment options across many serious conditions. Civorebrutinib has the potential to serve as a pipeline-in-a-product across multiple immune-mediated kidney diseases. Travere plans to investigate civorebrutinib in PMN, immune-mediated FSGS and MCD, with the potential for additional indications. These diseases share immune-mediated mechanisms that can lead to glomerular damage, resulting in proteinuria and impaired kidney function that may ultimately require dialysis or transplant. Civorebrutinib may also broaden future treatment approaches in FSGS, where both nephroprotective and targeted immune control approaches may play important roles.

Under the terms of the agreement, Everest will receive an upfront payment of $112.5 million in exchange for granting Travere exclusive development and commercialization rights for civorebrutinib in all markets outside of China and certain countries in East and Southeast Asia. Everest is also eligible to receive up to approximately $1.03 billion in additional cash payments tied to specified clinical development, regulatory and commercial milestones across up to five indications. Travere will also pay tiered royalties on future sales in its licensed territories, ranging from high single-digit to double-digit percentages based on annual net sales thresholds. The license agreement will become effective upon satisfaction of customary conditions, including expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended.

Conference Call Information

Travere Therapeutics will host a conference call and webcast today, Tuesday, June 2, 2026, at 8:30 a.m. ET. To participate in the conference call, dial +1 (833) 461-5787 (U.S.) or +1 (585) 542-9983 (International), conference ID 574 733 925 shortly before 8:30 a.m. ET. The webcast can be accessed on the Investor page of Travere’s website at ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company’s website.

About Civorebrutinib

Civorebrutinib (also known as EVER001) is a next-generation covalent reversible Bruton's tyrosine kinase (BTK) inhibitor in development globally for the treatment of renal diseases. BTK is an essential component of the B-cell receptor signaling pathways that regulate the survival, activation, proliferation, and differentiation of B lymphocytes. Targeting BTK with small molecule inhibitors has been demonstrated to be an effective treatment option for B-cell autoimmune diseases.

About Travere Therapeutics

At Travere Therapeutics, we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow. For more information, visit travere.com.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.

Forward Looking Statements

This press release contains “forward-looking statements” as that term is defined in the Private Securities Litigation Reform Act of 1995. Without limiting the foregoing, these statements are often identified by the words “on-track,” “positioned,” “look forward to,” “will,” “would,” “may,” “might,” “believes,” “anticipates,” “plans,” “expects,” “intends,” “potential,” or similar expressions. In addition, expressions of strategies, intentions or plans are also forward-looking statements. Such forward-looking statements include, but are not limited to, references to: statements regarding the Company's beliefs about the future potential of its pipeline and portfolio; statements regarding the Company's capabilities, competitive positioning, and strategic plans; statements and expectations regarding the potential of civorebrutinib to serve as a pipeline-in-a-product and to potentially become a best-in-class therapy across multiple immune-mediated kidney diseases, and its potential to provide differentiated efficacy, safety and convenience for the indications described herein; statements and expectations regarding the expected broad mechanistic applicability across diseases; statements and expectations regarding future treatment approaches and paradigms; statements and expectations regarding the clinical studies and data described herein; statements and expectations regarding potential future payments (including upfront, milestone and royalty payments) and, as applicable, the potential achievement and timing thereof; statements and expectations regarding the activities of the Company’s partners and collaborators; and statements related to the estimated sizes of patient populations. Such forward-looking statements are based on current expectations and involve inherent risks and uncertainties, including factors that could delay, divert or change any of them, and could cause actual outcomes and results to differ materially from current expectations. No forward-looking statement can be guaranteed. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties related to the license agreement with Everest, including the ability of the parties to obtain required regulatory approvals and satisfy other applicable conditions, and the ability of the Company to successfully advance the product through clinical trials toward potential future regulatory approval. The Company also faces risks and uncertainties related to its business and finances in general, the success of its commercial products, risks and uncertainties associated with its preclinical and clinical stage pipeline, risks and uncertainties associated with the regulatory review and approval process, risks and uncertainties associated with enrollment of clinical trials for rare diseases, and risks that ongoing or planned clinical trials may not succeed or may be delayed for safety, regulatory or other reasons. Specifically, the Company faces risks associated with the commercial launch of FILSPARI in FSGS and the ongoing commercialization in IgAN, the timing and potential outcome of its and its partners’ clinical studies, market acceptance of its commercial products including efficacy, safety, price, reimbursement, and benefit over competing therapies, risks related to the challenges of manufacturing scale-up, risks associated with the successful development and execution of commercial strategies for such products, including FILSPARI, and risks and uncertainties related to the current administration, including but not limited to risks and uncertainties related to tariffs and the funding, staffing and prioritization of resources at government agencies including the FDA. The Company also faces the risk that it will be unable to raise additional funding that may be required to complete development of any or all of its product candidates, including as a result of macroeconomic conditions; risks relating to the Company’s dependence on contractors for clinical drug supply and commercial manufacturing; uncertainties relating to patent protection and exclusivity periods and intellectual property rights of third parties; risks associated with regulatory interactions; and risks and uncertainties relating to competitive products, including current and potential future generic competition with certain of the Company’s products, including potential ANDA filings or patent challenges, and technological changes that may limit demand for the Company’s products. The Company also faces additional risks associated with global and macroeconomic conditions, including health epidemics and pandemics, including risks related to potential disruptions to clinical trials, commercialization activity, supply chain, and manufacturing operations. You are cautioned not to place undue reliance on these forward-looking statements as there are important factors that could cause actual results to differ materially from those in forward-looking statements, many of which are beyond our control. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events, or otherwise. Investors are referred to the full discussion of risks and uncertainties, including under the heading “Risk Factors”, as included in the Company’s most recent Form 10-K, Form 10-Q and other filings with the Securities and Exchange Commission.

View source version on businesswire.com: https://www.businesswire.com/news/home/20260602830373/en/

Call it the chicken revolution, but fast-food chains are betting on poultry to win back customers, and McDonald's (MCD +0.01%) won't be left behind. The iconic hamburger chain is upgrading its brand with new chicken offerings, including bone-in wings, as well as refreshed beverage options and restaurants, to compete with fast-casual rivals. 

McDonald's new growth strategy is called McDonald's > NEXT, with a main focus on higher-quality food and drink items, restaurant redesigns, and improved customer experience.

Is this a gimmick investors should ignore, or can the Golden Arches win again in a challenging consumer environment?

Today's Change

(

0.01

%) $

0.04

Current Price

$

284.81

The fast-food company not only wants to differentiate itself but is also emphasizing the challenging consumer environment, where discretionary dollars are limited. Consumers expect more for their money, and the McDonald's > NEXT strategy aims to address this by offering value deals and enhanced hospitality.

McDonald's is taking a necessary and calculated risk with its reimagining of the fast-food experience. An upgraded menu could put pressure on the company's margins, as premium ingredients cost more. Still, the long-term return on investment could be substantial if hungry consumers consistently choose McDonald's over rivals such as Starbucks or Chipotle.

Image source: Getty Images.

There is always a risk that new menu items or restaurant redesigns could be complete misses. If the chicken items fall short of the standards set by Raising Cane's or Chick-fil-A, consumers won't waste valuable dollars on subpar items. The strategy depends entirely on whether McDonald's can deliver on value and taste.

Shares of McDonald's are down 9% this year and are trading at a reasonable price. McDonald's stock has underperformed over the past five years so that a successful growth strategy could reinvigorate the 86-year-old American institution.

The stock's trailing P/E ratio is currently below 23, and with a quarterly dividend of $1.86 per share, McDonald's investors could see renewed growth alongside solid income.

New items will be tested in a limited number of stores before being rolled out more widely. This gives McDonald's a real opportunity to get its recipes for food and growth right. Long-term, I think this new focus is just what the brand needs.

Catie Hogan has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Chipotle Mexican Grill and Starbucks. The Motley Fool recommends the following options: long January 2028 $320 calls on McDonald's, short January 2028 $340 calls on McDonald's, and short June 2026 $36 calls on Chipotle Mexican Grill. The Motley Fool has a disclosure policy.

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them.

© Kittyfly / Shutterstock.com

A 65-year-old retiree with $1 million who follows the standard 4% rule withdraws $40,000 in the first year, then increases that amount over time to keep pace with inflation. A dividend-focused alternative starts slightly lower, at about $38,000 in annual income from a 3.8% blended yield, but does not require selling shares. Over 20 years, that difference can add up to roughly $370,000 to $430,000 in favor of the dividend approach. The driver is dividend growth, and the math deserves a careful look.

The Income Goal for a $1 Million Portfolio For decades, the 4% rule has served as a benchmark for retirement withdrawals. Based on research by William Bengen and later supported by the Trinity Study, the approach assumes retirees withdraw about 4% of their portfolio in the first year and then adjust that amount for inflation over time. More recent research from Morningstar has suggested a slightly lower starting withdrawal rate of 3.7% for new retirees. Either way, a $1 million portfolio is generally expected to generate about $37,000 to $40,000 in annual income. With the 10-year Treasury yield near 4.5% and the federal funds rate around 4%, today’s interest-rate environment is considerably more favorable for income investors seeking to generate cash flow without regularly selling portfolio assets.

Conservative Tier: 3% to 4% Yield $40,000 divided by 0.035 equals roughly $1,143,000. On a $1 million base, a 3.5% blended yield delivers about $35,000 in year one, but it grows. This is the Dividend Aristocrat and Dividend King zone, populated by names like Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction), Procter & Gamble (NYSE:PG), and McDonald’s (NYSE:MCD).

JNJ just lifted its quarterly payout to $1.34, its 64th consecutive annual increase, and yields about 2.3%. P&G yields 2.9% with a streak stretching back to 1890. McDonald’s pays 2.7%, with the quarterly dividend stepping from $0.94 in 2017 to $1.86 today. A low yield to start, but the income compounds.

Moderate Tier: 5% to 7% Yield $40,000 divided by 0.06 equals roughly $667,000. This is the range for high-dividend equity funds, preferred shares, REITs, covered-call ETFs, and mature telecoms. Verizon (NYSE:VZ) yields 5.8% at a 12 P/E, with the quarterly dividend climbing from $0.615 in 2020 to $0.7075 today. The tradeoff is plain in the price chart: VZ returned about 15% over five years, versus roughly 54% for JNJ. You get more income now, but dividend growth slows and the principal does less heavy lifting.

Aggressive Tier: 8% to 14% Yield $40,000 divided by 0.10 equals $400,000. This is BDC, mortgage REIT, leveraged covered-call, and high-yield bond territory. The income arrives, but principal erosion is common and distributions get cut in recessions. Dividend aristocrats fell about 1% in 2020 while selected high-yield SPDR funds fell 21% during 2008-09. The aggressive tier funds your present at the expense of your future.

The Insight That Reverses the Tiers A 3.5% yield growing 7% a year roughly doubles within a decade. Path B starts at $38,000 in year one and reaches about $147,000 by year 20, with cumulative dividends near $1,560,000. The 4% rule, by contrast, sells shares each year, which is why sequence-of-returns risk can leave the ending portfolio anywhere from $400,000 to $1.8 million. Dividends, paid from corporate cash flow, behave differently: S&P 500 dividends fell only 8% from the 2008 peak to the 2009 trough while share prices dropped 57%.

Microsoft (NASDAQ:MSFT) shows the same engine at maximum extension. The yield is only about 0.8%, but the quarterly dividend rose from $0.39 in 2017 to $0.91 now, while the stock returned roughly 864% over ten years. Growth on either end of the dividend pays for the patience.

Three Actions Before You Commit Audit your actual spending, not your salary. The per-capita disposable income of $68,359 sets a benchmark, but your fixed costs may need less coverage than you assume, especially once Social Security and Medicare offset healthcare. Compare a dividend-growth fund’s 10-year total return against a 10% covered-call fund. The compounding gap is the entire argument and it shows up cleanly on a chart of distributions plus price. Map the tax treatment to your bracket. Qualified dividends sit in the 0% or 15% long-term capital gains brackets for most retirees; non-qualified distributions are taxed as ordinary income against the 2026 standard deduction of $32,200 for joint filers. The tier you pick should survive that filter.

Dividend stocks that have fallen to 52-week lows can be enticing options to buy. When share prices drop, that means the yield you're collecting rises, since it means it costs less to acquire a piece of the business, and thus, the dividend income represents a greater proportion of the money you invest. Plus, at a lower price, there's the potential to profit from a rise in price should the stock rally in the future.

Three dividend stocks that recently hit new lows that you may want to consider buying today include McDonald's (MCD +0.15%), AT&T (T +1.13%), and Unilever (UL +0.78%).

Image source: Getty Images.

McDonald's Few companies in the world are as iconic as McDonald's. Its golden arches can be a welcome sight for travelers as the fast-food chain often represents a convenient and relatively low-cost option for a quick meal.

While prices have risen in recent years due to inflation, its restaurants still provide consumers with plenty of value, as evidenced by its continued growth. In the quarter ending March 31, McDonald's reported comparable sales growth of 3.8%, with performance broadly similar across international and domestic markets. It's a good sign of continually strong demand for its products.

Today's Change

(

0.15

%) $

0.44

Current Price

$

285.21

McDonald's may not be a growth machine, but it is certainly a dependable and stable long-term investment. And, of course, let's not forget the dividend income you can generate from this investment. At 2.6%, its yield is more than double the S&P 500 average of 1%. The stock is down around 8% this year and recently hit a new 52-week low, but with a reasonable price-to-earnings (P/E) multiple of 23, it can be a great pick up today, as this is a top dividend stock you can comfortably hang on to for the long haul.

AT&T Shares of AT&T have been falling recently as investors grow more concerned that SpaceX and its Starlink business may disrupt the broader telecom market. It's an issue that looks overblown, or at best, premature. Starlink is part of SpaceX's connectivity segment, which generated $11.4 billion in revenue last year. AT&T, by comparison, reported revenue that was 11 times that amount last year -- $125.6 billion.

AT&T is a top telecom provider, and while competition may chip away at some of its market share, the stock's recent decline represents a bit of an overreaction simply due to SpaceX gaining more attention of late as a result of its upcoming IPO. However, AT&T stock isn't exactly tumbling over a cliff; it's down around 9% for the year.

Today's Change

(

1.13

%) $

0.26

Current Price

$

23.26

For dividend investors, this could be an opportune time to buy this low-volatility stock, as its yield is up around 4.9% right now. AT&T's stock is trading near its lows, and its valuation is enticing -- its P/E multiple is just seven.

Unilever Top consumer brand Unilever is another dividend stock that's been struggling of late. Its shares are down 12% this year, making its decline the most significant on this list. The market has been concerned with the news that the company is looking to spin off its food business and the uncertainty that might bring.

While it might make the business smaller, Unilever sees it as an opportunity to be more of a pure play home and personal care company. That can help drive efficiency and allow the company to be more focused in its growth efforts. And although the food segment is a key one for Unilever, it was also its slowest-growing one in its most recent quarter, with management saying that "category conditions remained soft" in developed markets.

Today's Change

(

0.78

%) $

0.46

Current Price

$

58.77

Unilever stock currently yields right around 4%, making it another excellent income stock to buy and hold. And with its price declining, the stock's valuation looks attractive, as it trades at a P/E ratio of just over 19.

With the rate environment stabilizing in mid-2026, income investors are circling back to a familiar playbook: own the businesses that have raised payouts through every cycle in living memory. Dividend Kings and Aristocrats with 25-plus years of consecutive hikes offer a growing cash payment backed by durable franchises that the bond market still struggles to match consistently. Three names stand out this June for combining proven dividend track records with reasonable forward multiples and recent earnings momentum.

Here are the three dividend growth stocks worth a close look this month.

This infographic highlights key financial metrics, Q1 2026 performance, and growth outlooks for Johnson & Johnson (JNJ), Coca-Cola (KO), and McDonald’s (MCD). It details why these Dividend Kings and Aristocrats are considered top choices for dividend growth investors in June 2026. Johnson & Johnson (NYSE: JNJ) Johnson & Johnson (NYSE:JNJ | JNJ Price Prediction) is the gold standard of dividend longevity. The healthcare giant just declared its 64th consecutive annual increase, raising the quarterly payout 3% to $1.34 per share, paid on June 9, 2026. That puts JNJ in a club almost no public company can claim membership in.

The fundamentals back the streak. Q1 2026 revenue came in at $24.06 billion, up 10% year over year, beating the $23.61 billion estimate. Management raised full-year guidance to $100.3 billion to $101.3 billion in revenue with adjusted EPS of $11.45 to $11.65. Oncology is doing the heavy lifting: DARZALEX grew 23% to $3.96 billion and TREMFYA jumped 68% to $1.61 billion. CEO Joaquin Duato said the company is “delivering on its promise for a year of accelerated growth and impact.”

Shares are up 16% year to date through June 9, yet the forward multiple sits at just 20x earnings with a 2% yield and an analyst target of $252.87. The caveat: STELARA biosimilar erosion drove sales down 60% to $656 million, and a planned Orthopaedics separation introduces execution risk. The pipeline is broad enough to absorb the hit, but it is a real near-term headwind to monitor.

Coca-Cola (NYSE: KO) Coca-Cola (NYSE:KO) is the other beverage Dividend King in this group, with 63 consecutive years of dividend increases and $8.8 billion paid out to shareholders in 2025. The current quarterly dividend stands at $0.53 per share, with the next ex-dividend date on June 15, 2026.

Q1 2026 was a standout. Revenue hit $12.47 billion, up 12% year over year, with EPS of $0.86 versus $0.81 expected, the fourth straight beat. Global unit case volume rose 3%, led by China, the US, and India, while Coca-Cola Zero Sugar volume grew 13% across all segments. Operating margin expanded to 35% from 33%. Management lifted full-year guidance to 4% to 5% organic revenue growth and 8% to 9% comparable EPS growth, with free cash flow targeted at roughly $12.2 billion.

KO trades at a forward P/E of 24x with a 3% yield, and the stock has run 20% year to date against an analyst target of $86.06. The risk worth flagging: acquisitions and divestitures are a ~4% headwind, and Asia Pacific comparable operating income fell 17%. CEO Henrique Braun framed the quarter as reflecting “our unwavering focus on staying close to the consumer, executing locally and managing complexity.”

McDonald’s (NYSE: MCD) McDonald’s (NYSE:MCD) rounds out the list as the relative value play. The stock is down 6% year to date, trading well below its 200-day moving average of $306.47, even as the burger giant continues a streak of 49-plus consecutive years of dividend increases as a Dividend Aristocrat. The current quarterly dividend of $1.86 reflects a 5% raise from October 2025.

Q1 2026 showed the operating engine reaccelerating. Revenue rose 9% to $6.52 billion, EPS landed at $2.83 versus $2.74 expected, and global comparable sales jumped 4% after going negative a year ago. US comps grew 4%, and loyalty systemwide sales topped $9 billion in the quarter across 70 markets. CEO Chris Kempczinski put it directly: “McDonald’s delivered this quarter. Our 6% global Systemwide sales growth shows how we executed with discipline, proving that we can drive results even in a challenging environment.”

The numbers behind the thesis: a 3% yield, forward P/E of 22x, operating margin in the mid-to-high 40% range, and an analyst price target of $331.29. Roughly 2,600 new restaurants are planned for 2026. The caveat investors should weigh: a negative shareholders’ equity deficit of $1.79 billion, ongoing restructuring charges from Accelerating the Organization continuing through 2027, and tariff/trade exposure on the input side.

Why These Three, Why Now Each of these names cleared the same screen: a multi-decade history of dividend increases, recent earnings momentum confirmed by the most recent quarter, and a forward multiple that does not require heroic assumptions to justify. JNJ and KO offer the dividend longevity premium with current-year tailwinds, while MCD offers the discount entry on a Dividend Aristocrat trading below its 200-day average. For investors seeking proven income compounders as rates stabilize, the bar these three clear is hard to replicate elsewhere in the large-cap universe.

© RiverNorthPhotography / iStock Unreleased via Getty Images

McDonald’s (NYSE:MCD | MCD Price Prediction) is the rare mega-cap where the business is accelerating while the stock sits still. Global comps grew 3.8% last quarter, loyalty sales topped $9 billion in 90 days, and revenue jumped 9.4% YoY. Yet shares are down 5.67% year to date.

I think the disconnect creates an opportunity. The question I want to answer here: can McDonald’s stock realistically hit $375 by 2028? That is the bold target. Here is the math behind it.

Why McDonald’s Shares Are Stuck Despite Strong Fundamentals The stock closed at $284.77 on June 11, well below the 52-week high of $337.56. Performance has been ugly in pockets: down 3.33% over one year and off nearly 5.67% YTD, even after a 4.42% bounce last week.

The reasons are real. CEO Chris Kempczinski acknowledged on the Q1 call that the macro backdrop “is certainly not improving, and it may be getting a little bit worse,” with low-income spending still declining.

Beef inflation, higher interest expense (guided up 4 to 6% in 2026), and ongoing restructuring charges through 2027 are squeezing the narrative. With a beta of just 0.414, MCD is built to grind steadily higher rather than spike.

Wall Street Sees Modest Upside. Here’s What It’s Missing Consensus target sits at $331.29, with 5 Strong Buy, 14 Buy, 14 Hold, and 1 Sell rating. Our model’s base case lands at $322.66 over 12 months, with a bull scenario of $349.85 and a bear case of $298.80. Confidence is 90%, which is high.

My view: analysts are anchoring to near-term beef costs and underrating the loyalty flywheel. TTM loyalty sales already exceed $38 billion across 70 markets. With 56% bullish analyst skew already in place, the upside surprise is operational leverage, not sentiment.

The Path to $375 Per Share Reaching $375 from today’s price of $284.77 would require a gain of 31.7%. With forward EPS of $13.40, a price of $375 implies a forward P/E of 28x. Our base case of $322.66 already implies 23x, meaning the bold target requires roughly 5x of additional multiple expansion.

Is that achievable? I think yes, but only if three things happen. First, the 247Factor adjustment of 1.074 needs to keep expanding as comps stay positive. Second, the “McDonald’s NEXT” strategic repositioning and the ArchIQ AI drive-thru rollout with Google have to start showing margin lift.

Third, the chicken category, which Kempczinski called “bigger than beef globally, and it’s growing 2x faster,” needs to keep taking share. Add the FIFA World Cup 2026 marketing push and a 50,000-restaurant footprint target by 2027, and the EPS denominator does the work. The primary risk is a deeper consumer recession that stalls comps and forces value-driven margin compression.

Where McDonald’s Trades Today vs Its Earnings Power At $284.77, MCD trades at roughly 21x forward earnings, below its trailing P/E of 23 and the forward P/E of 22. Shares sit between a 52-week low of $270.15 and a high of $337.56. Over the past decade, MCD has returned 194.66%, proving the compounding case. For a defensive name throwing off a 2.61% yield and $7.19 billion in annual free cash flow, that multiple looks like value.

$375 Is a Stretch, But Here’s Why It’s Possible Reaching $375 by 2028 requires a 31.7% gain and a forward multiple near 28x. That is a stretch, but not a long shot.

Three things need to go right: loyalty members keep driving systemwide sales above 6%, the chicken and beverage platforms scale internationally, and EPS compounds toward $14 to $15. A consumer recession deeper than today’s pressure would derail it. Returns at this level shouldn’t be expected every year, but we’ve outlined the blueprint for how McDonald’s could reach $375 in 2028.

-

SEATTLE--(BUSINESS WIRE)--Starbucks Corporation (NASDAQ: SBUX) today announced that Brian Niccol, chairman and chief executive officer, will participate in a keynote fireside chat at the 6th Annual Evercore Consumer and Retail Conference on Tuesday, June 9th, 2026, at 11:40 a.m. Eastern Time.

The fireside chat will be webcast live from the company’s Investor Relations website at https://investor.starbucks.com on the Events & Presentations page.

About Starbucks

Since 1971, Starbucks Coffee Company has been committed to responsibly sourcing and roasting high-quality arabica coffee. Today, with a global footprint of more than 41,000 company-operated and licensed coffeehouses and a growing presence in consumer-packaged goods, we are the world's premier purveyor of specialty coffee. Through our unwavering commitment to excellence and our guiding principles, we bring the unique Starbucks Experience to life for every customer through every cup. To share in the experience, please visit us in our stores or online at about.starbucks.com or www.starbucks.com.

More News From Starbucks Corporation

Back to Newsroom

Starbucks' shares fall 9% in a month, but improving traffic, rewards growth, innovation and margin recovery efforts may support a turnaround.

Did Starbucks Corporation Insiders Breach their Fiduciary Duties to Shareholders? PR Newswire NEW YORK, June 5,

Starbucks' latest drink launch is a bet on the future of fast food beverages By You're currently following this author! Want to unfollow? Unsubscribe via the link in your email.

Starbucks is aiming to capitalize on social media trends and demand from younger consumers. Starbucks Starbucks isn't just launching another drink. With its latest Refreshers debut, announced Monday, the coffee giant is expanding one of its fastest-growing businesses as it races to win customers long after the morning coffee rush ends.

Beginning July 14, Starbucks customers will be able to order any Refresher drink blended, the latest move in the company's effort to expand what executives describe as a $2 billion beverage platform.

The launch follows April's rollout of customizable Energy Refreshers, which Starbucks executives said recently exceeded expectations and helped drive new customer occasions.

Refreshers, which are iced juice and tea drinks often mixed with fruit pieces, have become one of Starbucks' biggest beverage businesses since launching in 2012, helping drive traffic later in the day as the company looks to expand beyond its traditional morning coffee roots.

"The success of Refreshers reflects an evolution in how customers are engaging with Starbucks, with a growing preference for cold, customizable beverages alongside our core coffee offerings," Dana Pellicano, Starbucks' senior vice president of global product experience, told Business Insider.

Starbucks said Refreshers are helping drive growth in afternoon visits, an area the company has increasingly focused on as it seeks new sources of traffic. It sees customization as a key reason for the platform's success.

The strategy reflects a broader shift underway across the restaurant industry, as chains compete not only with each other but also with energy drinks, functional beverages, and social-media-fueled drink trends for younger consumers' attention and spending.

"Since Refreshers first launched in 2012, we've seen increased interest in drinks that are flavor-forward, visually compelling, and easy to personalize," Pellicano added.

"Chains are no longer just competing with each other for coffee occasions," Noah Pozin, a food, agribusiness, and beverage industry consultant at Truist, told Business Insider. "They are competing with energy drink brands, bottled teas, functional waters, and customized soda concepts for the broader 'cold, caffeinated, customizable treat' occasion."

Chasing younger tastesDutch Bros has expanded its energy-drink offerings, which executives say now account for about 25% of its business. Customized soda chains have also surged in popularity, and restaurant brands from McDonald's to Taco Bell are investing heavily in cold beverages. Analysts at JPMorgan and KeyBanc have pointed to a growing pipeline of innovation from both Starbucks and Dutch Bros as chains race to capture demand for customizable, functional drinks.

Part of what's driving that demand is a shift in how younger consumers think about beverages.

"Gen Z and millennials treat beverages more like personal expression, social content, functional fuel, and affordable indulgence," Pozin said.

Starbucks competitor Dutch Bros says customized energy drinks, such as its Myst Energy Refreshers, now account for roughly 25% of its business.  Illustration by Mario Tama/Getty Images As younger consumers navigate persistent inflation, housing affordability challenges, and broader economic uncertainty, beverages have become a relatively accessible luxury, he said. Consumers are increasingly looking for opportunities to experiment, customize, and discover new products without making a major purchase.

That trend has made beverages especially attractive to restaurant operators. Drinks typically carry higher margins than many food offerings and can help drive customer frequency throughout the day, making them an increasingly important growth engine for chains seeking new revenue streams.

Social media has only accelerated the trend.

"One of the biggest insights for us has been just how creative customers are with Refreshers," Pellicano said. "From early on, we saw customers take the core beverages and make them their own — whether that was swapping in coconut milk, which led to the creation of the Pink Drink, or layering in new flavors, textures, and colors."

"What started as customization quickly became culture," she added.

Pellicano said social media has become a "real-time feedback loop and source of inspiration" for Starbucks, helping the company spot emerging drink trends and scale them more quickly.

With blended Refreshers arriving this summer — and additional innovations already in the pipeline — Starbucks is signaling that its future growth won't come solely from coffee.

Read next

Katherine Tangalakis-Lippert is a senior reporter on Business Insider's West Coast team. When she's not writing about trending business and tech news, from the latest supply chain snarls or advancements in AI, she covers the food and restaurant industries, specifically companies such as Starbucks and McDonald's.Some of her prior areas of focus have included coverage of the Supreme Court and emerging technologies such as quantum computing.Katherine has worked on award-nominated projects and has appeared on Good Morning America, NBC, CNN, and other outlets to discuss her reporting.Prior to joining Business Insider, she covered retail, hospitality, and nonprofits at the San Fernando Valley Business Journal and received a master's degree in investigative reporting from the University of Southern California.Reach outDo you have feedback or a story tip? Contact Katherine on Signal at byktl.50, or email her at [email protected] her on Twitter and Instagram @scrawlgirl.Some of her recent scoops, exclusives, and original stories include: Starbucks set up a new office. It's a 5-minute drive from the CEO's California home.Inside Starbucks' crackdown on cup notesEndless Shrimp was Red Lobster's rock bottom. Now it's clawing back.Chipotle's new PAC signals a change in how the company engages in politicsKFC lost its footing in the Chicken Wars. Now it's gunning for a 'Kentucky Fried Comeback.'A few other highlights include: Clarence Thomas raised him 'as a son.' Now he's facing 25-plus years on weapons and drug charges.Call her Ivanka Kushner'Maybe I'll just resign:' Federal workers react to DOGE productivity emailSpaceX launches cause late-night booms that rattle windows, set off car alarms, and may damage property. Locals are pushing back.The US-China tech race is moving from chips to the raw materials they're made of

Starbucks Drinks Fast Food More Business

Starbucks is weighing options for its Japanese ​business, including a stake sale, Bloomberg ‌News reported on Tuesday.

Starbucks (SBUX) concluded the recent trading session at $98.76, signifying a +1.39% move from its prior day's close.

Cincinnati Financial Corporation reported improved Q1 2026 results, but profitability remains structurally weak with ROE below the cost of equity. CINF's underwriting profitability lags peers, making earnings more exposed to volatile investment income, especially due to its aggressive equity allocation. The stock trades at a premium valuation (1.6x book), which appears stretched given its high single-digit ROE and sector comparisons.

WTW Q1 results reflect solid performance across both segments, growth in the Investments business, an increase in adjusted operating income and expanded margin.

CINCINNATI, Ohio, May 4, 2026 /PRNewswire/ -- Cincinnati Financial Corporation (Nasdaq: CINF) today announced that based on preliminary voting results at the company's annual meeting on May 2, 2026, shareholders elected all directors for one-year terms to the 14-member board. Shareholders also approved the Amended and Restated Articles of Incorporation, the nonbinding resolution to approve the compensation for the company's named executive officers and ratified the selection of Deloitte & Touche LLP as independent registered public accounting firm for 2026.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Getting big returns from financial portfolios, whether through stocks, bonds, ETFs, other securities, or a combination of all, is an investor's dream. But for income investors, generating consistent cash flow from each of your liquid investments is your primary focus.

While cash flow can come from bond interest or interest from other types of investments, income investors hone in on dividends. A dividend is that coveted distribution of a company's earnings paid out to shareholders, and investors often view it by its dividend yield, a metric that measures the dividend as a percent of the current stock price. Many academic studies show that dividends make up large portions of long-term returns, and in many cases, dividend contributions surpass one-third of total returns.

Headquartered in Fairfield, Cincinnati Financial (CINF - Free Report) is a Finance stock that has seen a price change of 0.01% so far this year. The insurer is currently shelling out a dividend of $0.94 per share, with a dividend yield of 2.3%. This compares to the Insurance - Property and Casualty industry's yield of 0.77% and the S&P 500's yield of 1.43%.

Looking at dividend growth, the company's current annualized dividend of $3.76 is up 8% from last year. Over the last 5 years, Cincinnati Financial has increased its dividend 5 times on a year-over-year basis for an average annual increase of 8.39%. Looking ahead, future dividend growth will be dependent on earnings growth and payout ratio, which is the proportion of a company's annual earnings per share that it pays out as a dividend. Cincinnati Financial's current payout ratio is 37%, meaning it paid out 37% of its trailing 12-month EPS as dividend.

Looking at this fiscal year, CINF expects solid earnings growth. The Zacks Consensus Estimate for 2026 is $8.61 per share, which represents a year-over-year growth rate of 8.30%.

From greatly improving stock investing profits and reducing overall portfolio risk to providing tax advantages, investors like dividends for a variety of different reasons. But, not every company offers a quarterly payout.

Big, established firms that have more secure profits are often seen as the best dividend options, but it's fairly uncommon to see high-growth businesses or tech start-ups offer their stockholders a dividend. Income investors have to be mindful of the fact that high-yielding stocks tend to struggle during periods of rising interest rates. With that in mind, CINF is a compelling investment opportunity. Not only is it a strong dividend play, but the stock currently sits at a Zacks Rank of #3 (Hold).